AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria
Jinxin Zheng,Xiaoju Liu,Yanpeng Xiong,Qingyin Meng,Peiyu Li,Fan Zhang,Xiaoming Liu,Zhiwei Lin,Qiwen Deng,Zewen Wen,Zhijian Yu
DOI: https://doi.org/10.1080/22221751.2024.2321981
2024-03-02
Emerging Microbes & Infections
Abstract:The rapid proliferation of multidrug-resistant (MDR) bacterial pathogens poses a serious threat to healthcare worldwide. Carbapenem-resistant (CR) Enterobacteriaceae, which have near-universal resistance to available antimicrobials, represent a particularly concerning issue. Herein, we report the identification of AMXT-1501, a polyamine transport system inhibitor with antibacterial activity against Gram-positive and -negative MDR bacteria. We observed minimum inhibitory concentration (MIC) 50 /MIC 90 values for AMXT-1501 in the range of 3.13–12.5 μM (2.24–8.93 μg /mL), including for methicillin-resistant Staphylococcus aureus (MRSA), CR Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa . AMXT-1501 was more effective against MRSA and CR E. coli than vancomycin and tigecycline, respectively. Subinhibitory concentrations of AMXT-1501 reduced the biofilm formation of S. aureus and Enterococcus faecalis . Mechanistically, AMXT-1501 exposure damaged microbial membranes and increased membrane permeability and membrane potential by binding to cardiolipin (CL) and phosphatidylglycerol (PG). Importantly, AMXT-1501 pressure did not induce resistance readily in the tested pathogens.
immunology,infectious diseases,microbiology